<ѻý>Trial Questions Role of Dual Immunotherapy in First-Line NSCLCѻý> In Japanese trial, nivolumab-ipilimumab didn't improve OS versus pembrolizumab, had more toxicity Aug 22, 2024
<ѻý>Researchers Challenge USPSTF's Lung Cancer Screening Criteriaѻý> Alternate criteria based on years of smoking has higher sensitivity and specificity, study says Aug 20, 2024
<ѻý>Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancerѻý> Lazertinib plus amivantamab improved PFS by about 7 months versus single-agent osimertinib Aug 20, 2024
<ѻý>Higher Steroid Dose for ICI Toxicity Harms Cancer Survival, Analysis Suggestsѻý> More data for discussion of controversial association between steroids, immunotherapy Aug 19, 2024
<ѻý>FDA Expands Durvalumab Label to Operable Lung Cancerѻý> PD-L1 checkpoint inhibitor approved for use in NSCLC before and after surgery Aug 16, 2024
<ѻý>Cancer Screening Costs Over $43 Billion a Year in the U.S., Study Estimatesѻý> Colorectal cancer screening accounted for 64% of the total amount Aug 05, 2024
<ѻý>FDA Panel Supports More Clarity in NSCLC Perioperative Immunotherapy Trialsѻý> Committee unanimously backs mandating trial design to distinguish effects of therapy phases Jul 25, 2024
<ѻý>Vapers May Be Less Likely to Undergo Lung Cancer Screeningѻý> "Former smokers who use e-cigarettes remain at increased risk of lung cancer," researchers say Jul 02, 2024
<ѻý>Real-World Analysis Identifies Meds Tied to Higher Risk of Liver Injuryѻý> Case reports may not be as reliable, researchers say Jun 25, 2024
<ѻý>Court: Some Employers Can Exclude PrEP, Cancer Screenings From Insurance Coverageѻý> Not all preventive care recommended by the USPSTF is threatened by the narrow ruling, however Jun 24, 2024
<ѻý>Anti-PD-L1 Plus Targeted Agent No Better Than Chemo for Resistant NSCLCѻý> No significant difference between atezolizumab-cabozantinib, docetaxel for OS, PFS, response Jun 20, 2024
<ѻý>Early Menopause Tied to Higher Risk of Respiratory Mortalityѻý> Greatest risk observed for women with bilateral oophorectomy Jun 13, 2024
<ѻý>Another KRAS Inhibitor Scores an Early Win in Advanced Non-Small Cell Lung Cancerѻý> Half of patients responded, but editorialists call for new directions in therapy development Jun 11, 2024
<ѻý>Dendritic Cell Therapy Offers No Survival Advantage in Pleural Mesotheliomaѻý> Immunotherapy may have been given too late, researchers suggested Jun 10, 2024
<ѻý>Lung Cancer Screening Rates Remain Low in the U.S., Especially in the Southѻý> But one study showed that patient navigation added to usual care may increase uptake Jun 10, 2024
<ѻý>Artery Inflammation and CV Events; Stepped Palliative Care for Lung Cancer Patientsѻý> Also in TTHealthWatch: diets and medicine in IBS and active surveillance in prostate cancer Jun 08, 2024 podcast
<ѻý>Limited-Stage SCLC Gets a New Standard of Care With Consolidation Durvalumabѻý> Median OS was 55.9 months in the durvalumab group compared with 33.4 months in the placebo group Jun 03, 2024
<ѻý>'Practice Changing' Trial for Inoperable Locally Advanced NSCLCѻý> EGFR testing now needed for all patients with stage III disease, experts say Jun 02, 2024
<ѻý>Virtual and In-Person Palliative Care Equally Beneficial in Advanced Lung Cancerѻý> No differences observed in quality of life metric, patient and caregiver satisfaction Jun 02, 2024
<ѻý>Subcutaneous Amivantamab Plus Lazertinib Non-Inferior to IV Dosing in NSCLCѻý> Unexpectedly offers a possible overall survival benefit, researchers say Jun 01, 2024
<ѻý>Novel Bispecific in EGFR-Mutant Lung Cancer Boosts PFS After Targeted Agentsѻý> China-based trial may present a hurdle to FDA approval, however Jun 01, 2024
<ѻý>Unprecedented PFS Results in ALK-Positive Lung Cancer Trialѻý> "We have not seen anything close to this," says expert May 31, 2024
<ѻý>Smoking Isn't the Only Source of Nicotine Addiction in Townѻý> Emerging data suggest pharmacological interventions may help patients quit vaping May 29, 2024
<ѻý>Psychostimulant No Help in Relieving Cancer-Related Fatigueѻý> No significant differences in outcomes between methylphenidate, placebo May 22, 2024
<ѻý>FDA OKs Novel BiTE Agent for Small Cell Lung Cancerѻý> First-in-class tarlatamab achieved a 40% ORR in previously treated extensive-stage SCLC May 16, 2024
<ѻý>Perioperative Nivolumab Boosts EFS in Resectable Lung Cancerѻý> CheckMate 77T trial shows 42% reduction in risk of tumor recurrence, progression, or death May 15, 2024
<ѻý>Will AI Replace Radiologists, or Just Make Them Better Than Ever?ѻý> Opinions differ on how much physicians should be embracing the technology May 14, 2024
<ѻý>Glecirasib Shows Promising Efficacy in KRAS-Mutated NSCLCѻý> Trend towards better response rate, PFS compared with approved KRAS inhibitors May 01, 2024
<ѻý>EPA Bans Consumer Use of Toxic Chemical Known to Cause Liver, Lung Cancersѻý> Methylene chloride has killed at least 88 workers since 1980 Apr 30, 2024
<ѻý>White House Indefinitely Delays Plan to Ban Menthol Cigarettesѻý> Biden administration has delayed the final rule several times recently Apr 26, 2024
<ѻý>Alectinib Lands FDA Approval for Adjuvant Therapy in NSCLCѻý> The ALK inhibitor reduced the risk of recurrence or death by 76% versus chemotherapy Apr 19, 2024
<ѻý>Accelerated Aging Linked to Recent Increase in Early-Onset Solid Tumorsѻý> Strength of association increased in more recent birth cohorts Apr 09, 2024
<ѻý>Can Late-Stage Cancer Incidence Serve as an Endpoint for Screening Trials?ѻý> Study shows it may be an alternative to cancer-specific mortality for some cancers, but not all Apr 08, 2024
<ѻý>Enhertu Gets Tumor-Agnostic FDA Approval for HER2-Positive Cancersѻý> About half of patients responded, duration of response as long as 19 months in three trials Apr 05, 2024
<ѻý>Forget 'Pack-Years' for Lung Cancer Screening Eligibility, Study Suggestsѻý> Switching to just a 20-year duration of smoking could catch more cancers, eliminate disparities Apr 01, 2024
<ѻý>Graphic Images on Cigarettes of Smoking's Harm Are Constitutional, Court Rulesѻý> Partial victory for federal regulators seeking to toughen warning labels Mar 22, 2024
<ѻý>EPA Bans Asbestos, a Deadly Carcinogen Still in Use Decades After Partial Banѻý> New rule would prohibit chrysotile asbestos Mar 19, 2024
<ѻý>First-Line Immunotherapy Alone Sufficient for Older NSCLC Patients, Study Suggestsѻý> Retrospective analysis finds similar OS, PFS whether or not patients also received chemotherapy Mar 07, 2024
<ѻý>FDA OKs Amivantamab as First-Line Lung Cancer Treatmentѻý> Bispecific drug lands full approval for NSCLCs with EGFR exon 20 insertion mutations Mar 04, 2024
<ѻý>Changing the Surgical Paradigm in Oligometastatic NSCLCѻý> Propensity-score matched analysis suggests survival benefit with surgery to the primary tumor Feb 23, 2024